Avandia Should Stay On Market With Warnings, Committee Says
Executive Summary
FDA's Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees are calling for strengthened warnings for GlaxoSmithKline's type 2 diabetes drug Avandia due to cardiovascular safety concerns, but not its withdrawal from the market